NAV

Sabatolimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sabatolimab
DrugBank Accession Number
DB16322
Background

Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).

Type
Biotech
Groups
Investigational
Synonyms
  • Anti-tim-3 monoclonal antibody mbg453
  • Anti-tim3 checkpoint inhibitor mbg453
  • Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer
  • Immunoglobulin g4-kappa, anti-(homo sapiens havcr2 (hepatitis a virus cellular receptor 2, t-cell immunoglobulin mucin family member 3, tim-3, tim3, timd3, cd366)), humanized monoclonal antibody
  • Sabatolimab
External IDs
  • MBG 453
  • MBG-453
  • MBG453

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

ATC Codes
L01FX19 — Sabatolimab
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3L7R886Y06
CAS number
2252262-24-9

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia1
2CompletedTreatmentMyelodysplastic Syndrome1
2Not Yet RecruitingTreatmentMyelodysplastic Syndrome1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2RecruitingTreatmentMyelodysplastic Syndrome1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia / Bone marrow disorder / Chronic Myelomonocytic Leukemia / Hematologic Disease and Disorders / Leukemias / Myelodysplastic Syndrome / Myeloid Leukemias1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia / High-risk Myelodysplastic Syndrome (MDS)1
1Active Not RecruitingTreatmentGlioblastoma Multiforme (GBM)1
1RecruitingTreatmentMyelodysplastic Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 15, 2020 20:02 / Updated at February 21, 2021 18:55